Gene therapy for blood cancer shows 73 per cent response rate in clinical trials

Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-income countries, patients in whom 'B-cell' tumours continue to grow following a period of remission (relapse), or do not respond to treatment (refractory), suffer from poor outcomes due to an absence of effective therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y7GjvrF
via IFTTT